Biomarker Menu
Biomarker Menu

Explore Our Biomarker Menu

Including 400+ Biomarker Offerings for a Range of Disease States

Return to Biomarker Menu

Biomarker: TIM-1

Search for Biomarkers





Rat Urine

Disease State:



Experienced Running

Required Sample Volume:

50 µL/well


LLOQ: 0.01 ng/mL
ULOQ: 2.46 ng/mL

Biological or Clinical Significance:

Hepatitis A virus cellular receptor 1 (HAVcr-1) also known as T-cell immunoglobulin and mucin domain 1 (TIM-1) is a protein that in humans is encoded by the HAVCR1 gene. The hepatitis A virus cellular receptor 1 (HAVCR1/TIM-1), is a member of the TIM (T cell transmembrane, immunoglobulin, and mucin) gene family, which plays critical roles in regulating immune cell activity especially regarding the host response to viral infection. TIM-1 is also involved in allergic response, asthma, and transplant tolerance.

TIM genes are also involved in host-virus interaction. As receptors for phosphatidylserine, TIM proteins bind many families of viruses that include viruses such as dengue and ebola. Interestingly entry of Lassa fever virus, influenza A virus, and SARS coronavirus were not affected by TIM-1 expression. TIM-1 and TIM-4 enhanced viral entry more than TIM-3.


Speak to a Scientist

    What would you like to discuss?

    With whom will we be speaking?

    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

    Yes I confirm that I am over the age of 16 and I consent to communications from BioAgilytix.

    biomarker services


    See how our premier bioanalytical services support all phases of biomarker, immunogenicity, PK, and cell-based assay studies.

    Explore our services

    case studies

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.

    Read our case studies